RecruitingNot ApplicableNCT05864794

Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial


Sponsor

University Medical Center Groningen

Enrollment

100 participants

Start Date

May 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether routinely doing a brain MRI scan in people newly diagnosed with stage IV (metastatic) non-small cell lung cancer — even when they have no brain symptoms — helps catch brain metastases early and improves treatment decisions. **You may be eligible if...** - You have been diagnosed with stage IV (metastatic) non-small cell lung cancer (NSCLC) - You have not yet started treatment for your stage IV disease - You have no symptoms suggesting cancer has spread to the brain - You are well enough to receive systemic cancer treatment (PS 0–2) **You may NOT be eligible if...** - You have already started treatment for your metastatic lung cancer - Your lung cancer has a specific targetable mutation (like EGFR, ALK, ROS1, RET, MET, or BRAF) for which approved targeted drugs exist - You cannot have an MRI with contrast dye Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMRI

MRI scan of the brain


Locations(3)

University Medical Center Groningen

Groningen, Provincie Groningen, Netherlands

Maastricht UMC+

Maastricht, Netherlands

Ommelander Ziekenhuisgroep

Scheemda, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05864794


Related Trials